Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

17.98 +0.10 (+0.56%)

Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Relay Therapeutics CFO Sells 17,717 Shares for $350,000 ↗

September 02, 2026

Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics (NASDAQ:RLAY) Reports Q2 2026 Revenue Miss as Loss Widens Slightly ↗

August 06, 2026

Via Chartmill

Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year ↗

June 29, 2026

This precision oncology innovator, up nearly 500% in a year, just reported significant insider selling amid ongoing drug development efforts.

Via The Motley Fool

Topics Regulatory Compliance

Is Relay Therapeutics a Buy After Promising Trial Results? ↗

May 22, 2026

Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.

Via The Motley Fool

Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance ↗

May 05, 2026

Via Chartmill

Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Preview: Relay Therapeutics's Earnings ↗

August 06, 2025

Via Benzinga

Why Relay Therapeutics Stock Popped on Wednesday ↗

May 20, 2026

In a way, this was a delayed reaction to excellent news from the lab.

Via The Motley Fool

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗

May 18, 2026

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗

May 18, 2026

Energy Vault Holdings develops modular, grid-scale energy storage systems for utilities and large-scale power users.

Via The Motley Fool

Topics Regulatory Compliance

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

February 27, 2026

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Via The Motley Fool

Topics Regulatory Compliance

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗

February 06, 2026

This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains.

Via The Motley Fool

Topics Regulatory Compliance

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗

December 03, 2025

Sometimes insiders sell shares because their conviction is changing. Sometimes it's just about bookkeeping.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across...

Via TokenRing AI

Topics Artificial Intelligence Economy Emissions

Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗

November 06, 2025

Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029.

Via Chartmill

Topics Earnings

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗

September 05, 2025

The cancer-focused biotech has a bright future, according to one pundit.

Via The Motley Fool

Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 26, 2025

Via Benzinga

Relay (RLAY) Q2 Loss Narrows 41% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.